Atossa Therapeutics’ (ATOS) Buy Rating Reaffirmed at HC Wainwright

HC Wainwright reaffirmed their buy rating on shares of Atossa Therapeutics (NASDAQ:ATOS) in a report released on Wednesday,Benzinga reports. HC Wainwright currently has a $7.00 price target on the stock.

Several other brokerages also recently weighed in on ATOS. Ascendiant Capital Markets lifted their target price on shares of Atossa Therapeutics from $6.50 to $7.00 and gave the company a “buy” rating in a report on Monday, December 9th. StockNews.com downgraded shares of Atossa Therapeutics from a “hold” rating to a “sell” rating in a report on Monday, November 18th.

Atossa Therapeutics Stock Performance

Shares of Atossa Therapeutics stock opened at $0.72 on Wednesday. Atossa Therapeutics has a 1 year low of $0.70 and a 1 year high of $2.31. The company has a market capitalization of $90.16 million, a P/E ratio of -3.26 and a beta of 1.20. The company’s fifty day moving average is $0.84 and its two-hundred day moving average is $1.16.

Institutional Trading of Atossa Therapeutics

Several hedge funds and other institutional investors have recently made changes to their positions in the company. Gallagher Capital Advisors LLC acquired a new stake in shares of Atossa Therapeutics in the fourth quarter valued at about $25,000. Millennium Management LLC acquired a new stake in shares of Atossa Therapeutics in the fourth quarter valued at about $28,000. Intech Investment Management LLC acquired a new stake in shares of Atossa Therapeutics in the third quarter valued at about $29,000. Two Sigma Advisers LP lifted its stake in shares of Atossa Therapeutics by 214.1% in the fourth quarter. Two Sigma Advisers LP now owns 42,400 shares of the company’s stock valued at $40,000 after purchasing an additional 28,900 shares during the period. Finally, Wells Fargo & Company MN lifted its stake in shares of Atossa Therapeutics by 30.7% in the fourth quarter. Wells Fargo & Company MN now owns 71,720 shares of the company’s stock valued at $68,000 after purchasing an additional 16,853 shares during the period. Hedge funds and other institutional investors own 12.74% of the company’s stock.

About Atossa Therapeutics

Atossa Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops medicines in the areas of unmet medical need in oncology for women breast cancer and other conditions in the United States. The company's lead drug candidate is oral (Z)-endoxifen, an active metabolite of tamoxifen, which is in Phase II clinical trials to treat and prevent breast cancer.